Diagnostic Testing and Treatment Guidelines for COVID-19 and Influenza
The fully captioned video and edited transcript will be posted within the next few days.
Click here to view the recording with the integrated audio transcript using the password below.
Password: 9r+6G%U8
“Please note special time of this COCA Call.”
This COCA Call will be held on Friday, March 27, 2020
This COCA Call will be held on Friday, March 27, 2020
= Overview
Diagnostic testing for SARS-CoV-2 and influenza viruses can guide clinical management, including appropriate antiviral treatment, particularly in persons at higher risk for progression to severe disease from COVID-19 and influenza, regardless of vaccination status. Antivirals are available that can reduce the risk of severe illness and death from COVID-19 and mitigate influenza illness. During this COCA Call, subject matter experts will present an overview of COVID-19 and influenza therapeutic options, including eligibility, indications, and efficacy.
Presenters
Pragna Patel, MD, MPH
Chief Medical Officer
Coronavirus and Other Respiratory Viruses Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Tim Uyeki, MD, MPH, MPP
Chief Medical Officer
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Call Materials
When:
Thursday, February 1, 2024
2:00 PM – 3:00 PM ET
Webinar Link:
https://www.zoomgov.com/j/1613771800
Webinar ID: 161 377 1800
Passcode: 706943
Telephone:
+1 646 828 7666 US
One-tap mobile:
+16468287666,,1613771800#,,,,*706943# US
When:
Tuesday, July 26, 2022,
2:00 PM – 3:00 PM ET
Webinar Link:
https://www.zoomgov.com/j/1615119188
Passcode: 143543
Dial In:
US: +1 669 254 5252 or +1 646 828 7666 or +1 551 285 1373 or +1 669 216 1590
One-tap mobile:
US: +16692545252,,1615119188#,,,,*143543# or +16468287666,,1615119188#,,,,*143543#
Webinar ID: 161 511 9188
Add to Calendar
Due to the high demand we anticipate for this COCA Call, we encourage participants to consider viewing on Facebook. To see the call live, please click on COCA’s Facebook Page.
Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC4520R—Diagnostic Testing and Treatment Guidelines for COVID-19 and Influenza—please visit CDC TRAIN and search for the course in the Course Catalog using WC4520R-020124. Follow the steps below by March 4, 2024.
To receive continuing education (CE) for WD4520R—Diagnostic Testing and Treatment Guidelines for COVID-19 and Influenza—please visit CDC TRAIN and search for the course in the Course Catalog using WD4520R-020124. Follow the steps below between March 5, 2024, and March 5, 2026.
- Register for and complete the course.
- Pass the post-assessment at 75%.
- Complete the evaluation.
- Visit Your Learning to access your certificates and transcript.
ACCREDITATION STATEMENTS
In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA CME: Credit Designation Statement – Live
The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.
CPE: The Centers for Disease Control and Prevention designated this Knowledge-based event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-24-015-L04-P and enduring JA4008229-0000-24-016-H04-P.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.
AAVSB/RACE: This program has been submitted (but not yet approved) for 1 hours of continuing education credit in jurisdictions which recognize AAVSB RACE approval; however, participants should be aware that some boards have limitations on the number of hours accepted in certain categories or restrictions on certain methods of delivery of continuing education.
For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters/moderators must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education.
Sign up to receive COCA Call Announcements, COCA Newsletters and other COCA resources by entering your email address: